Roger Pearse is an Oncology physician affiliated with NewYork–Presbyterian Hospital. OpenAlex indexes 170 publications with 4,109 citations (h-index 27); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
520 E 70th St # Starr-341
New York, NY 100219800
Telephone
212-746-3964Registry record last updated 16 Sept 2011.
Clinical trials
- Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Sponsor: Weill Medical College of Cornell University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year20251 payment
- ZOLL Medical CorporationProgram year20211 payment
- GlaxoSmithKline, LLC.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
83.5%CD38-directed Cytolytic Antibody64%Daratumumab100%Part B, office-administered≥46 patientsProteasome Inhibitor19.6%Carfilzomib74%Bortezomib26%Part B, office-administered≥25 patientsAnti-infectives
11.5%Human Immunoglobulin G11.5%Immune globulin100%Part B, office-administered≥47 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor0%Valacyclovir100%Part D<11 patientsMusculoskeletal
3.4%RANK Ligand Inhibitor3.3%Denosumab100%Part B, office-administered≥13 patientsBisphosphonate0.1%Zoledronic acid100%Part B, office-administered≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1994–2010 per NIH RePORTER. The latest:
- Neurotrophin Signaling in Multiple Myeloma
Weill Medical Coll of Cornell Univ
FY2010$231,642R01CA113639 - Neurotrophin Signaling in Multiple Myeloma
Weill Medical Coll of Cornell Univ
FY2009$231,642R01CA113639 - Neurotrophin Signaling in Multiple Myeloma
Weill Medical Coll of Cornell Univ
FY2008$231,642R01CA113639
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Clerkin, MD
NewYork–Presbyterian Hospital
Brandon Swed, MD
NewYork–Presbyterian Hospital
Richard Mayeux, MD
NewYork–Presbyterian Hospital
Lawrence Lenke, MD
NewYork–Presbyterian Hospital
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”